Faecalibacterium prausnitzii
Faecalibacterium is a genus of bacteria. The genus contains several species including Faecalibacterium prausnitzii, Faecalibacterium butyricigenerans, Faecalibacterium longum, Faecalibacterium duncaniae, Faecalibacterium hattorii, and Faecalibacterium gallinarum. Its first known species, Faecalibacterium prausnitzii is gram-positive, mesophilic, rod-shaped, and anaerobic, and is one of the most abundant and important commensal bacteria of the human gut microbiota. It is non-spore forming and non-motile. These bacteria produce butyrate and other short-chain fatty acids through the fermentation of dietary fiber. The production of butyrate makes them an important member of the gut microbiota, fighting against inflammation. — Wikipedia
Clinical trial activity
9 trials · 11 clinical orgs · 0 marketing orgs
Earliest trial started Oct 10, 2018 (NCT03728868)
Timeline
Indications
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFaecalibacterium ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07128680 | Phase 1 | Dec 5, 2025 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT06925061 | Phase 2 | Mar 31, 2025 | University of Paris |
| NCT06551272 | Phase 2 | Dec 1, 2024 | Center Eugene Marquis |
| NCT06253611 | Phase 2 | Jul 31, 2024 | Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR), University of Paris |
| NCT06448572 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2024 | Exeliom Biosciences, University of Lille |
| NCT06306014 | Phase 1/Phase 2 (Phase 2) | May 7, 2024 | Exeliom Biosciences, University of Lyon |
| NCT05542355 | Phase 1 | Sep 15, 2022 | Exeliom Biosciences, Robarts Clinical Trials |
| NCT04938843 | N/A | Aug 16, 2021 | Metabogen, University of Gothenburg |
| NCT03728868 | N/A | Oct 10, 2018 | Metabogen, University of Gothenburg |
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exeliom Biosciences | For profit | 3 | 1 | 2 | 2022 |
| Metabogen | For profit | 2 | 1 | 1 | 2018 |
| University of Gothenburg | Academic/Hospital | 2 | 1 | 1 | 2018 |
| University of Paris | Academic/Hospital | 2 | 1 | 1 | 2024 |
| Center Eugene Marquis | Academic/Hospital | 1 | 1 | 1 | 2024 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2025 |
| Robarts Clinical Trials | For profit | 1 | 0 | 1 | 2022 |
| University of Lille | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Lyon | Academic/Hospital | 1 | 1 | 1 | 2024 |